Parkinson’s disease as a somato-cognitive action network disorder
Jianxun Ren, Wei Zhang, Louisa Dahmani, Evan M. Gordon, Shenshen Li, Ying Zhou, Yang Long, Jianting Huang, Yafei Zhu, Ning Guo, Changqing Jiang, Feng Zhang, Yan Bai, Wei Wei, Yaping Wu, Alan Bush, Matteo Vissani, Luhua Wei, Carina R. Oehrn, Melanie A. Morrison, Ying Zhu, Chencheng Zhang, Qingyu Hu, Yilin Yin, Weigang Cui, Xiaoxuan Fu, Ping Zhang, Weiwei Wang, Gong-Jun Ji, Ji He, Kai Wang, Dongsheng Fan, Zhaoxia Wang, Teresa J. Kimberley, Simon Little, Philip Starr, Robert Mark Richardson, Luming Li, Meiyun Wang, Danhong Wang, Nico U. F. Dosenbach, Hesheng Liu
Abstract
Parkinson’s disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symptoms, progressing to whole-body motor and cognitive symptoms1–5. Dysfunction of the somato-cognitive action network (SCAN)—which is thought to control action execution6,7 by coordinating arousal, organ physiology and whole-body motor plans with behavioural motivation—is a potential contributor to the diverse clinical manifestations of PD. To investigate the role of the SCAN in PD pathophysiology and treatments (medications, deep-brain stimulation (DBS), transcranial magnetic stimulation (TMS) and MRI-guided focused ultrasound stimulation (MRgFUS)), we built a large (n = 863), multimodal, multi-intervention clinical imaging dataset. Resting-state functional connectivity revealed that the substantia nigra and all PD DBS targets (subthalamic nucleus, globus pallidus and ventral intermediate thalamus) are selectively connected to the SCAN rather than to effector-specific motor regions. Importantly, PD was characterized by specific hyperconnectivity between the SCAN and the subcortex. We therefore followed six PD cohorts undergoing DBS, TMS, MRgFUS and levodopa therapy using precision resting-state functional connectivity and electrocorticography recording. Efficacious treatments reduced SCAN-to-subcortex hyperconnectivity. Targeting the SCAN instead of effector regions doubled the efficacy of TMS treatments. Focused ultrasound treatment benefits increased when the target was closer to the thalamic SCAN sweet spot. Thus, SCAN hyperconnectivity is central to PD pathophysiology and its alleviation is a hallmark of successful neuromodulation. Targeting functionally defined subcortical SCAN nodes may improve existing therapies (DBS, MRgFUS), whereas cortical SCAN targets offer effective non-invasive or minimally invasive neuromodulation for PD. The substantia nigra and all Parkinson’s disease deep-brain stimulation targets are selectively connected to the somato-cognitive action network rather than to effector-specific motor regions.